Wealthspire Advisors (Maryland)’s Royalty Pharma RPRX Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$2.21M	Buy	+52,560	New	+$2.26M	0.08%	121

Other funds holding RPRX

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

RWJF

Robert Wood Johnson Foundation Princeton, New Jersey $81M AUM 0.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s RPRX Position: Q3 2020 in Review

Wealthspire Advisors (Maryland) opened a new position in Royalty Pharma (RPRX) in Q3 2020: 52,560 shares worth $2.21M. The stake represents 0.08% of the portfolio and ranks #121 among its holdings.

134 funds tracked by Wall St. Rank hold RPRX as of Q3 2020.

Wealthspire Advisors (Maryland) held 52,560 shares of Royalty Pharma worth $2.21M as of Q3 2020.
Royalty Pharma was a new Wealthspire Advisors (Maryland) position in Q3 2020.
Royalty Pharma made up 0.08% of Wealthspire Advisors (Maryland)'s portfolio in Q3 2020, its #121 holding.
134 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2020.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q3 2020, filed 13 Nov 2020.